126 related articles for article (PubMed ID: 37013448)
1.
Mustansar T; Mirza T; Hussain M
Biotech Histochem; 2023 Nov; 98(6):382-390. PubMed ID: 37013448
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
3. Extended-spectrum of
Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
Benmokhtar S; Laraqui A; El Boukhrissi F; Hilali F; Bajjou T; Jafari M; El Zaitouni S; Baba W; El Mchichi B; Elannaz H; Lahlou IA; Chahdi H; Oukabli M; Mahfoud T; Tanz R; Ichou M; Ennibi K; Dakka N; Sekhsokh Y
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3725-3733. PubMed ID: 36444585
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutations upregulate Runx1 to promote occurrence of head and neck squamous cell carcinoma.
Deng M; Guo J; Ling Z; Zhang C; He L; Fan Z; Cheng B; Xia J
Mol Carcinog; 2023 Sep; 62(9):1284-1294. PubMed ID: 37222390
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations of the HRAS gene and absence of hotspot mutations of the BRAF genes in oral squamous cell carcinoma in a Greek population.
Koumaki D; Kostakis G; Koumaki V; Papadogeorgakis N; Makris M; Katoulis A; Kamakari S; Koutsodontis G; Perisanidis C; Lambadiari V; Chrysomali E; Stavrianeas N; Alexandridis C; Rigopoulos D
Oncol Rep; 2012 May; 27(5):1555-60. PubMed ID: 22294102
[TBL] [Abstract][Full Text] [Related]
8. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Bruckman KC; Schönleben F; Qiu W; Woo VL; Su GH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov; 110(5):632-7. PubMed ID: 20813562
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
10. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
[TBL] [Abstract][Full Text] [Related]
11. Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
Gupta R; Strbenac D; Satgunaseelan L; Cheung VK; Narayanappa H; Ashford B; Mitchell J; Thind A; Palme CE; Ch'ng S; Low TH; Wykes J; Willet CE; Chew T; Yang J; Ranson M; Clark JR
Mod Pathol; 2023 Aug; 36(8):100190. PubMed ID: 37080394
[TBL] [Abstract][Full Text] [Related]
12. Effect of photodynamic therapy on expression of HRAS, NRAS and caspase 3 genes at mRNA levels, apoptosis of head and neck squamous cell carcinoma cell line.
Yousefi M; Koopaie M; Karimi R; Kermani FM; Kolahdooz S; Shamshiri A
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102142. PubMed ID: 33307231
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Cohen Y; Goldenberg-Cohen N; Shalmon B; Shani T; Oren S; Amariglio N; Dratviman-Storobinsky O; Shnaiderman-Shapiro A; Yahalom R; Kaplan I; Hirshberg A
Oral Oncol; 2011 Oct; 47(10):946-50. PubMed ID: 21824802
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines.
Maemoto S; Yumoto M; Ibata M; Torizuka S; Ozawa N; Tatsumi S; Hashido M; Morikawa M; Maeda G; Imai K
Odontology; 2012 Jul; 100(2):149-55. PubMed ID: 21607592
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings.
Pązik M; Michalska K; Żebrowska-Nawrocka M; Zawadzka I; Łochowski M; Balcerczak E
BMC Cancer; 2021 Feb; 21(1):130. PubMed ID: 33549031
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
Trietsch MD; Spaans VM; ter Haar NT; Osse EM; Peters AA; Gaarenstroom KN; Fleuren GJ
Gynecol Oncol; 2014 Oct; 135(1):149-55. PubMed ID: 25072932
[TBL] [Abstract][Full Text] [Related]
17. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
[TBL] [Abstract][Full Text] [Related]
19. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
